CoChat

Therapeutic resistance to anti-oestrogen therapy in breast cancer

Open access
Will, Marie, Liang, Jackson, Metcalfe, Ciara, Chandarlapaty, Sarat · 2023 · Nature Reviews Cancer
Cited by 176

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Although selective antagonism of oestrogen receptor signalling in breast cancer has been one of the most successful therapeutic approaches in oncology, resistance is a major clinical challenge. In this Review, Will et al. explore mechanisms of oestrogen-receptor-α-targeted therapeutic resistance and strategies to overcome it. The hormone receptor oestrogen receptor-α (ER) orchestrates physiological mammary gland development, breast carcinogenesis and the progression of breast tumours into lethal, treatment-refractory systemic disease. Selective antagonism of ER signalling has been one of the most successful therapeutic approaches in oncology, benefiting patients as both a cancer preventative measure and a cancer treatment strategy. However, resistance to anti-oestrogen therapy is a major clinical challenge. Over the past decade, we have gained an understanding of how breast cancers evolve under the pressure of anti-oestrogen therapy. This is best depicted by the case of oestrogen-independent mutations in the gene encoding ER ( ESR1 ), which are virtually absent in primary breast cancer but highly prevalent (20–40%) in anti-oestrogen-treated metastatic disease. These and other findings highlight the ‘evolvability’ of ER^+ breast cancer and the need to understand molecular processes by which this evolution occurs. Recent development and approval of next-generation ER antagonists to target ESR1 -mutant breast cancer underscores the clinical importance of this evolvability and sets a new paradigm for the treatment of ER^+ breast cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41568-023-00604-3

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 148

  1. Brisken, C. & O’Malley, B. Hormone action in the mammary gland. Cold Spring Harb. Perspect. Biol. 2, a003178 (2010). · DOI · Paper page
  2. DeSantis, C. E. et al. Breast cancer statistics, 2019. CA Cancer J. Clin. 69, 438–451 (2019). · DOI · Paper page
  3. Giaquinto, A. N. et al. Breast cancer statistics, 2022. CA Cancer J. Clin. 72, 524–541 (2022). · DOI · Paper page
  4. Eeckhoute, J., Carroll, J. S., Geistlinger, T. R., Torres-Arzayus, M. I. & Brown, M. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev. 20, 2513–2526 (2006). · DOI · Paper page
  5. Waks, A. G. & Winer, E. P. Breast cancer treatment: a review. J. Am. Med. Assoc. 321, 288–300 (2019). · DOI · Paper page
  6. Hartkopf, A. D., Grischke, E. M. & Brucker, S. Y. Endocrine-resistant breast cancer: mechanisms and treatment. Breast Care 15, 347–354 (2020). · DOI
  7. Johnston, S. R. D. & Dowsett, M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat. Rev. Cancer 3, 821–831 (2003). · DOI · Paper page
  8. Patel, H. K. & Bihani, T. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol. Ther. 186, 1–24 (2018). · DOI · Paper page
  9. Sakamoto, T. et al. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells. Mol. Cell. Endocrinol. 192, 93–104 (2002). · DOI
  10. Liu, H., Lee, E. S., Deb Los Reyes, A., Zapf, J. W. & Jordan, V. C. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. Cancer Res. 61, 3632–3639 (2001).
  11. Shang, Y. & Brown, M. Molecular determinants for the tissue specificity of SERMs. Science 295, 2465–2468 (2002). · DOI · Paper page
  12. Jordan, V. C. Tamoxifen: catalyst for the change to targeted therapy. Eur. J. Cancer 44, 30–38 (2008). · DOI · Paper page
  13. Gottardis, M. M. & Jordan, V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 48, 5183–5187 (1988).
  14. Wolf, D. M. & Jordan, V. C. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res. Treat. 31, 117–127 (1994). · DOI
  15. Wakeling, A. E. Therapeutic potential of pure antioestrogens in the treatment of breast cancer. J. Steroid Biochem. Mol. Biol. 37, 771–775 (1990). · DOI
  16. Wakeling, A. E., Dukes, M. & Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 51, 3867–3873 (1991).
  17. Long, X. & Nephew, K. P. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha. J. Biol. Chem. 281, 9607–9615 (2006). · DOI · Paper page
  18. Wardell, S. E., Marks, J. R. & McDonnell, D. P. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem. Pharmacol. 82, 122–130 (2011). · DOI · Paper page
  19. Guan, J. et al. Therapeutic ligands antagonize estrogen receptor function by impairing its mobility. Cell 178, 949–963.e18 (2019). · DOI · Paper page
  20. Stenoien, D. L. et al. FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent. Nat. Cell Biol. 3, 15–23 (2001). · DOI · Paper page
  21. Sutherland, R. L., Green, M. D., Hall, R. E., Reddel, R. R. & Taylor, I. W. Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur. J. Cancer Clin. Oncol. 19, 615–621 (1983). · DOI · Paper page
  22. Butler, W. B. & Kelsey, W. H. Effects of tamoxifen and 4-hydroxytamoxifen on synchronized cultures of the human breast cancer cell line MCF-7. Breast Cancer Res. Treat. 11, 37–43 (1988). · doi:10.1007/bf01807556
  23. Watts, C. K. W., Sweeney, K. J. E., Warlters, A., Musgrove, E. A. & Sutherland, R. L. Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res. Treat. 31, 95–105 (1994). · DOI
  24. Musgrove, E. A. et al. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell Biol. 13, 3577–3587 (1993).
  25. Elledge, R. M. et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int. J. Cancer 89, 111–117 (2000). · DOI · Paper page
  26. Yamashita, H. et al. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer 13, 74–83 (2006). · DOI
  27. Najjar, S. & Allison, K. H. Updates on breast biomarkers. Virchows Arch. 480, 163–176 (2022). · DOI
  28. Bonneterre, J. et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J. Clin. Oncol. 18, 3748–3757 (2000). · DOI · Paper page
  29. Nabholtz, J. M., Bonneterre, J., Buzdar, A., Robertson, J. F. & Thürlimann, B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur. J. Cancer 39, 1684–1689 (2003). · DOI · Paper page
  30. Mauri, D., Pavlidis, N., Polyzos, N. P. & Ioannidis, J. P. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J. Natl Cancer Inst. 98, 1285–1291 (2006). · DOI · Paper page
  31. Watts, C. K. & King, R. J. Overexpression of estrogen receptor in HTB 96 human osteosarcoma cells results in estrogen-induced growth inhibition and receptor cross talk. J. Bone Min. Res. 9, 1251–1258 (1994). · DOI
  32. Schiff, R. et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin. Cancer Res. 10, 331s–336s (2004). · DOI · Paper page
  33. Musheyev, D. & Alayev, A. Endocrine therapy resistance: what we know and future directions. Explor. Target. Antitumor Ther. 3, 480–496 (2022). · DOI
  34. Zhang, Q. X., Borg, A., Wolf, D. M., Oesterreich, S. & Fuqua, S. A. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 57, 1244–1249 (1997). Following the initial identification of a case in 1997, a series of publications (Toy et al., Robinson et al., Merenbakh-Lamin et al., Li et al. and Jeselsohn et al.) in the early 2010s identified a collection of activating ESR1 mutations to be recurrent, acquired mechanisms of resistance to anti-oestrogen therapy in metastatic ER+ breast cancer.
  35. Toy, W. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439–1445 (2013). This study characterizes the activity and drug sensitivity of various ESR1 mutations as well as the therapeutic potential of oral SERDs in antagonizing ESR1 mutants. · DOI · Paper page
  36. Robinson, D. R. et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446–1451 (2013). · DOI · Paper page
  37. Merenbakh-Lamin, K. et al. D538G mutation in estrogen receptor-α: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 73, 6856–6864 (2013). · DOI · Paper page
  38. Li, S. et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 4, 1116–1130 (2013). · DOI · Paper page
  39. Jeselsohn, R. et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin. Cancer Res. 20, 1757–1767 (2014). · DOI · Paper page
  40. Toy, W. et al. Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov. 7, 277–287 (2017). · DOI · Paper page
  41. Chandarlapaty, S. et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol. 2, 1310–1315 (2016). · DOI · Paper page
  42. Razavi, P. et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34, 427–438.e6 (2018). This study dissects the genomic data of more than 1,500 ER+ breast tumours and incorporates clinical treatment and outcomes to define acquired alterations that may contribute to resistance to hormonal therapy. · DOI · Paper page
  43. Schiavon, G. et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci. Transl. Med. 7, 313ra182 (2015). This study highlights the clinical acquisition of ESR1 mutants in patients with ER+ breast cancer using serial sampling of circulating tumour DNA. · DOI · Paper page
  44. Kuang, Y. et al. Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. npj Breast Cancer 4, 22 (2018). · DOI
  45. Fribbens, C. V. et al. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA (ctDNA) in metastatic breast cancer. J. Clin. Oncol. 35, 1015–1015 (2017). · doi:10.1200/jco.2017.35.15_suppl.1015
  46. Katzenellenbogen, J. A., Mayne, C. G., Katzenellenbogen, B. S., Greene, G. L. & Chandarlapaty, S. Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. Nat. Rev. Cancer 18, 377–388 (2018). · DOI · Paper page
  47. Fanning, S. W. et al. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. eLife 5, e12792 (2016).
  48. Gates, L. A. et al. Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets. Oncogene 37, 4581–4598 (2018). · DOI · Paper page
  49. Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M. & Schiff, R. ESR1 mutations — a mechanism for acquired endocrine resistance in breast cancer. Nat. Rev. Clin. Oncol. 12, 573–583 (2015). · DOI · Paper page
  50. Gu, G. et al. Hormonal modulation of ESR1 mutant metastasis. Oncogene 40, 997–1011 (2021). · DOI
  51. Li, Z. et al. Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis. Cancer Res. 82, 1321–1339 (2022). · DOI
  52. Harrod, A. et al. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene 36, 2286–2296 (2017). · DOI · Paper page
  53. Bahreini, A. et al. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Breast Cancer Res. 19, 60 (2017). · DOI · Paper page
  54. Martin, L. A. et al. Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nat. Commun. 8, 1865 (2017). · DOI
  55. Liang, J. et al. Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer. Sci. Transl. Med. 14, eabo5959 (2022). · DOI
  56. Najim, O. et al. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: a systematic review and meta-analysis of randomized and non-randomized trials. Biochim. Biophys. Acta Rev. Cancer 1872, 188315 (2019). · DOI
  57. Carlson, K. E., Choi, I., Gee, A., Katzenellenbogen, B. S. & Katzenellenbogen, J. A. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 36, 14897–14905 (1997). · DOI · Paper page
  58. Zhao, Y. et al. Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors. Cancer Res. 77, 5602–5613 (2017). · DOI
  59. van Kruchten, M. et al. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. Cancer Discov. 5, 72–81 (2015). · DOI · Paper page
  60. Ferraro, E., Walsh, E. M., Tao, J. J., Chandarlapaty, S. & Jhaveri, K. Accelerating drug development in breast cancer: new frontiers for ER inhibition. Cancer Treat. Rev. 109, 102432 (2022). · DOI
  61. Lei, J. T. et al. Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer. Cell Rep. 24, 1434–1444.e7 (2018). · DOI
  62. Hartmaier, R. J. et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann. Oncol. 29, 872–880 (2018). · DOI
  63. Giltnane, J. M. et al. Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci. Transl. Med. 9, eaai7993 (2017). · DOI
  64. Lei, J. T., Gou, X. & Ellis, M. J. ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer. Mol. Cell Oncol. 5, e1526005 (2018). · doi:10.1080/23723556.2018.1526005
  65. Lonard, D. M. & O’Malley B. W. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol. Cell 27, 691–700 (2007). · DOI · Paper page
  66. Osborne, C. K. et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl Cancer Inst. 95, 353–361 (2003). · DOI · Paper page
  67. Myers, E. et al. Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br. J. Cancer 91, 1687–1693 (2004). · DOI
  68. McBryan, J. et al. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Res. 72, 548–559 (2012). · DOI
  69. Keeton, E. K. & Brown, M. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-α and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol. Endocrinol. 19, 1543–1554 (2005). · DOI · Paper page
  70. Girault, I. et al. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin. Cancer Res. 9, 1259–1266 (2003).
  71. Prat, A. & Perou, C. M. Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 5, 5–23 (2011). · DOI · Paper page
  72. Knowlden, J. M. et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144, 1032–1044 (2003). · DOI · Paper page
  73. Dowsett, M. et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J. Clin. Oncol. 26, 1059–1065 (2008). · DOI · Paper page
  74. Nayar, U. et al. Acquired HER2 mutations in ER(+) metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nat. Genet. 51, 207–216 (2019). This study identifies HER2 activating mutations in metastatic biopsies of patients with ER+ breast cancer resistant to hormonal therapy. · DOI · Paper page
  75. Croessmann, S. et al. Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer. Clin. Cancer Res. 25, 277–289 (2019). · DOI
  76. Smyth, L. M. et al. Efficacy and determinants of response to HER kinase inhibition in HER2-mutant metastatic. Cancer Discov. 10, 198–213 (2020). · DOI
  77. Mao, P. et al. Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER(+) metastatic breast cancer. Clin. Cancer Res. 26, 5974–5989 (2020). · DOI · Paper page
  78. Lupien, M. et al. Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev. 24, 2219–2227 (2010). · DOI · Paper page
  79. Pearson, A. et al. Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance. Clin. Cancer Res. 26, 608–622 (2020). · DOI · Paper page
  80. Sokol, E. S. et al. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer. Ann. Oncol. 30, 115–123 (2019). · DOI · Paper page
  81. Adams, E. J. et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature 571, 408–412 (2019). · DOI · Paper page
  82. Seachrist, D. D., Anstine, L. J. & Keri, R. A. FOXA1: a pioneer of nuclear receptor action in breast cancer. Cancers 13, 5205 (2021). · DOI
  83. Quintanal-Villalonga, Á. et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat. Rev. Clin. Oncol. 17, 360–371 (2020). · DOI · Paper page
  84. Chan, J. M. et al. Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. Science 377, 1180–1191 (2022). · DOI · Paper page
  85. Hoefnagel, L. D. C. et al. Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases. Cancer 118, 4929–4935 (2012). · DOI
  86. Gutierrez, M. C. et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 23, 2469–2476 (2005). · DOI · Paper page
  87. Drury, S. C. et al. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr. Relat. Cancer 18, 565–577 (2011). · DOI · Paper page
  88. Ottaviano, Y. L. et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54, 2552–2555 (1994).
  89. Yang, X. et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 60, 6890–6894 (2000).
  90. Vesuna, F. et al. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α. Oncogene 31, 3223–3234 (2012). · DOI · Paper page
  91. Wang, L. & Sharma, A. The quest for orally available selective estrogen receptor degraders (SERDs). ChemMedChem 15, 2072–2097 (2020). · DOI
  92. Hernando, C. et al. Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective. Int. J. Mol. Sci. 22, 7812 (2021). · DOI
  93. Ozyurt, R. & Ozpolat, B. Molecular mechanisms of anti-estrogen therapy resistance and novel targeted therapies. Cancers 14, 5206 (2022). · DOI
  94. Willson, T. M. et al. 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J. Med. Chem. 37, 1550–1552 (1994). · DOI · Paper page
  95. Wu, Y. L. et al. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol. Cell 18, 413–424 (2005). · DOI · Paper page
  96. Bentrem, D. et al. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology 142, 838–846 (2001). · DOI
  97. Lloyd, M. R., Wander, S. A., Hamilton, E., Razavi, P. & Bardia, A. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. Ther. Adv. Med. Oncol. 14, 17588359221113694 (2022). · DOI · Paper page
  98. Wardell, S. E., Nelson, E. R., Chao, C. A., Alley, H. M. & McDonnell, D. P. Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader. Endocr. Relat. Cancer 22, 713–724 (2015). · DOI · Paper page
  99. Garner, F., Shomali, M., Paquin, D., Lyttle, C. R. & Hattersley, G. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs 26, 948–956 (2015). · DOI · Paper page
  100. Bihani, T. et al. Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has antitumor activity in multiple ER(+) breast cancer patient-derived xenograft models. Clin. Cancer Res. 23, 4793–4804 (2017). · DOI · Paper page
  101. Liang, J. et al. GDC-9545 (giredestrant): a potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast cancer. J. Med. Chem. 64, 11841–11856 (2021). · DOI
  102. Tolaney, S. M. et al. 212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER-advanced breast cancer (aBC). Ann. Oncol. 33, S634–S635 (2022). · doi:10.1016/j.annonc.2022.07.251
  103. Wang, Y. & Tang, S.-C. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options. Cancer Metastasis Rev. 41, 975–990 (2022). · DOI · Paper page
  104. Bardia, A. et al. AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2-advanced breast cancer. Ther. Adv. Med. Oncol. 14, 17588359221083956 (2022). · DOI
  105. Bardia, A. et al. EMERALD: phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. Future Oncol. 15, 3209–3218 (2019). · DOI
  106. Chen, Y. C. et al. Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer. Exp. Opin. Investig. Drugs 31, 515–529 (2022). · DOI
  107. Martin Jimenez, M. et al. 211MO giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): primary analysis of the phase II, randomised, open-label acelERA BC study. Ann. Oncol. 33, S633–S634 (2022). · DOI
  108. Oliveira, M. et al. Abstract GS3-02: GS3-02 camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: results of the randomized, multi-dose phase 2 SERENA-2 trial. Cancer Res. 83, GS3-02 (2023). · doi:10.1158/1538-7445.sabcs22-gs3-02
  109. Fasching, P. A. et al. Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2–eBC): final analysis of the randomized, open-label, international phase 2 coopERA BC study. J. Clin. Oncol. 40, 589–589 (2022). · DOI
  110. Békés, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181–200 (2022). · DOI · Paper page
  111. Flanagan, J. J. & Neklesa, T. K. Targeting nuclear receptors with PROTAC degraders. Mol. Cell. Endocrinol. 493, 110452 (2019). · DOI · Paper page
  112. Hamilton, E. P. et al. ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer: phase 1b cohort (part C) of a phase 1/2 study. J. Clin. Oncol. 40, TPS1120 (2022). · DOI · Paper page
  113. Puyang, X. et al. Discovery of selective estrogen receptor covalent antagonists for the treatment of ERα(WT) and ERα(MUT). Cancer Discov. 8, 1176–1193 (2018). · DOI · Paper page
  114. Furman, C. et al. Covalent ERα antagonist H3B-6545 demonstrates encouraging preclinical activity in therapy-resistant breast cancer. Mol. Cancer Ther. 21, 890–902 (2022). · DOI
  115. Hamilton, E. P. et al. Abstract P1-17-10: H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer — a phase II study. Cancer Res. 82, P1-17-10–P11-17-10 (2022). · doi:10.1158/1538-7445.sabcs21-p1-17-10
  116. Hamilton, E. P. et al. Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. J. Clin. Oncol. 39, 1018–1018 (2021). · DOI
  117. Gil-Gil, M. et al. The role of CDK4/6 inhibitors in early breast cancer. Breast 58, 160–169 (2021). · DOI
  118. Fassl, A., Geng, Y. & Sicinski, P. CDK4 and CDK6 kinases: from basic science to cancer therapy. Science 375, eabc1495 (2022). · DOI · Paper page
  119. Li, Z. et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway. Cancer Cell 34, 893–905.e8 (2018). · DOI · Paper page
  120. Yang, C. et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene 36, 2255–2264 (2017). · DOI · Paper page
  121. Cornell, L., Wander, S. A., Visal, T., Wagle, N. & Shapiro, G. I. MicroRNA-mediated suppression of the TGF-β pathway confers transmissible and reversible CDK4/6 inhibitor resistance. Cell Rep. 26, 2667–2680.e7 (2019). · DOI
  122. Li, Q. et al. INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors. Cancer Discov. 12, 356–371 (2021). · DOI · Paper page
  123. Turner, N. et al. Abstract GS3-04: GS3-04 capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III CAPItello-291 trial. Cancer Res. 83, GS3-04 (2023). · DOI
  124. Turner, N. et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70, 2085–2094 (2010). · DOI · Paper page
  125. Mohammed, H. et al. Progesterone receptor modulates ERα action in breast cancer. Nature 523, 313–317 (2015). This article highlights the role of PR in modulating ER function and behaviour. · DOI · Paper page
  126. Singhal, H. et al. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Sci. Adv. 2, e1501924 (2016). · DOI
  127. Cottu, P. H. et al. Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers. PLoS ONE 13, e0204973 (2018). · DOI
  128. Nishino, T., Ishibashi, K., Hirtreiter, C. & Nishino, Y. Potentiation of the antitumor effect of tamoxifen by combination with the antiprogestin onapristone. J. Steroid Biochem. Mol. Biol. 116, 187–190 (2009). · DOI
  129. Carroll, J. S., Hickey, T. E., Tarulli, G. A., Williams, M. & Tilley, W. D. Deciphering the divergent roles of progestogens in breast cancer. Nat. Rev. Cancer 17, 54–64 (2017). · DOI
  130. Gonzalez, L. O. et al. Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 8, 149 (2008). · DOI
  131. Collins, L. C. et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod. Pathol. 24, 924–931 (2011). · DOI · Paper page
  132. Niemeier, L. A., Dabbs, D. J., Beriwal, S., Striebel, J. M. & Bhargava, R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod. Pathol. 23, 205–212 (2010). · DOI · Paper page
  133. D’Amato, N. C. et al. Cooperative dynamics of AR and ER activity in breast cancer. Mol. Cancer Res. 14, 1054–1067 (2016). · DOI
  134. Cochrane, D. R. et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 16, R7 (2014). · DOI · Paper page
  135. Krop, I. et al. A randomized placebo controlled phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor-positive breast cancer. Clin. Cancer Res. 26, 6149–6157 (2020). · DOI
  136. Hickey, T. E. et al. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat. Med. 27, 310–320 (2021). This study dissects the role of AR activation in modulating resistance to hormonal therapy in breast cancer. · DOI · Paper page
  137. Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9–20 (2022). · DOI · Paper page
  138. Rugo, H. S. et al. Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR+/HER2−) advanced breast cancer. J. Clin. Oncol. 40, LBA1001 (2022). · DOI
  139. Stanton, S. E., Adams, S. & Disis, M. L. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2, 1354–1360 (2016). · DOI · Paper page
  140. Zhang, M. et al. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Oncotarget 8, 31347–31354 (2017). · DOI · Paper page
  141. Segovia-Mendoza, M. & Morales-Montor, J. Immune tumor microenvironment in breast cancer and the participation of estrogen and its receptors in cancer physiopathology. Front. Immunol. 10, 348 (2019). · DOI
  142. Vathiotis, I. A. et al. Immune checkpoint blockade in hormone receptor-positive breast cancer: resistance mechanisms and future perspectives. Clin. Breast Cancer 22, 642–649 (2022). · DOI
  143. Muller, M. et al. The immune landscape of human pancreatic ductal carcinoma: key players, clinical implications, and challenges. Cancers 14, 995 (2022). · DOI
  144. Li, X. et al. Immune checkpoint blockade in pancreatic cancer: trudging through the immune desert. Semin. Cancer Biol. 86, 14–27 (2022). · DOI
  145. Ullman, N. A., Burchard, P. R., Dunne, R. F. & Linehan, D. C. Immunologic strategies in pancreatic cancer: making cold tumors hot. J. Clin. Oncol. 40, 2789–2805 (2022). · DOI · Paper page
  146. Russo, M. & Bardelli, A. Lesion-directed therapies and monitoring tumor evolution using liquid biopsies. Cold Spring Harb. Perspect. Med. 7, a029587 (2017). · DOI
  147. Sant, M., Bernat-Peguera, A., Felip, E. & Margelí, M. Role of ctDNA in breast cancer. Cancers 14, 310 (2022). · DOI
  148. Rao, S. et al. Transcription factor-nucleosome dynamics from plasma cfDNA identifies ER-driven states in breast cancer. Sci. Adv. 8, eabm4358 (2022). · DOI

Cited by

See all 176

Metadata

Authors
Will, M., Liang, J., Metcalfe, C., & Chandarlapaty, S.
Venue
Nature Reviews Cancer
Published
2023-07-27
Volume
23
Issue
10
Pages
673-685
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
OpenAlex
W4385302644
Cited by
176
References
15
FWCI
8.79
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic resistance to anti-oestrogen therapy in breast cancer. https://app.cochat.ai/papers/10.1038/s41568-023-00604-3
The paper
Will, M., Liang, J., Metcalfe, C., & Chandarlapaty, S. (2023). Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nature Reviews Cancer. https://doi.org/10.1038/s41568-023-00604-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.